May 9, 2014Open Access

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

In melanoma cell lines, including BRAFi-resistant cells, PD-L1 expression is variably regulated by oncogenic signaling pathways. PD-L1-exposed lymphocytes decrease MAPK signaling, which is corrected by exposure to vemurafenib, providing potential benefits of combining this drug with immunotherapies.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Atefi et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69dd4c8a0644c7b49d40cc18 — DOI: https://doi.org/10.1158/1078-0432.ccr-13-2797

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib· 2012 · 2,145 citations
Abstract 3928: Inhibition of the ubiquitin proteasome system differentially regulates glucocorticoid receptor-mediated transcriptional processes· 2012 · 27 citations
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms· 2005 · 1,896 citations
Mutations of the BRAF gene in human cancer· 2002 · 10,654 citations

Authors

Mohammad Atefi

Earl Avramis

Amanda Lassen

Journals

Clinical Cancer Research

Actions

Institutions

University of California, Los Angeles

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion